Temple University Gastroparesis Clinical Center
['FUNDING_U01'] · TEMPLE UNIV OF THE COMMONWEALTH · NIH-11171447
This program follows people with gastroparesis to learn what causes symptoms, to look at immune and pyloric muscle changes, and to try treatments such as buspirone.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEMPLE UNIV OF THE COMMONWEALTH (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11171447 on ClinicalTrials.gov |
What this research studies
You can join the Gastroparesis Registry where Temple will enroll up to 400 people and follow them for 1–4 years to track symptoms, tests, and outcomes. The center runs ongoing projects including a clinical trial of buspirone for early satiety (BESST), a pathology study examining immune cell patterns in stomach tissue (PBG), and a new study of pyloric sphincter function. GpR3 has been expanded to collect information about how prior SARS‑CoV‑2 (COVID‑19) infection affects people with gastroparesis. Joining may involve clinic visits, questionnaires, medical testing, and in some studies a tissue biopsy.
Who could benefit from this research
Good fit: Adults with a diagnosis of gastroparesis who can attend clinic visits and agree to the required tests and follow‑up are the ideal candidates.
Not a fit: People without gastroparesis, those unable to travel to the clinic, or those who cannot undergo required tests or biopsies are unlikely to gain direct benefit from participating.
Why it matters
Potential benefit: If successful, this work could lead to better symptom relief, more targeted treatments, and clearer explanations of why gastroparesis happens.
How similar studies have performed: Past gastroparesis registries and clinical trials have improved understanding of symptoms and found some promising therapies, but many questions remain and elements like immune profiling and COVID‑19 effects are relatively new.
Where this research is happening
PHILADELPHIA, UNITED STATES
- TEMPLE UNIV OF THE COMMONWEALTH — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PARKMAN, HENRY PAUL — TEMPLE UNIV OF THE COMMONWEALTH
- Study coordinator: PARKMAN, HENRY PAUL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases